1. Stokes T, Shaw EH, Juarez-Garcia A, et al. Clinical guidelines and evidence review of the epilepsies: diagnosis and management in adults and children in primary and secondary care. London: Royal College of General Practitioner; 2004.
3. Sillanpää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain. 2006;129:617–24.
5. Ben-Menachem E, Sander JW, Privitera M, et al. Measuring outcomes of treatment with antiepileptic drugs in clinical trials. Epilepsy & Behav. 2010;18:24–30.
7. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:2016–26.
8. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402–8.
9. Trinka E, Marson AG, Paesschen VW. KOMET: an unblinded, randomized, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. Neurology. 2013;84:1138–47.
10. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Eng J Med. 2000;342:314–9.
11. Lason W, Dudra-Jastrzebska M, Rejdak K, et al. Basic mechanism of antiepileptic drugs and their pharmacokinetic/pharmacodynamics interactions: an update. Pharmacol Reports. 2011;63:271–92.
12. Stephen LJ, Brodie MJ. Antiepileptic drug monotherapy versus poly-therapy: pursuing seizure freedom and tolerability in adults. Curr Opin Neurol. 2012;25:164–72.
13. Brigo F, Ausserer H, Tezzon F, et al. When one plus one makes three: the quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy. Epilepsy Behav. 2013;27:439–42.
14. Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)—part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013;52:927–66.
15. Jacoby A, Snape D, Baker GA. Determinants of quality of life in people with epilepsy. Neurol Clin. 2009;27:843–63.
16. Battino D, Landmark CJ, Tomson T. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia. 2013;54:405–14.
17. Nadebaum C, Anderson V, Vajda F, et al. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc. 2011;17:133–42.
18. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of an-tiepileptic drugs during pregnancy. Neurology. 2012;78:1692–9.
19. Mawhinney E, Craig J, Morrow , et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology. 2013;80:400–5.
20. Artma M, Gissler M, Malm H, et al. Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland. Drug Saf. 2013;36:359–69.
22. Ahmad BS, Hill KD, O’Brien TJ, et al. Falls and fractures in patients chronically treated with antiepileptic drugs. Neurology. 2012;79:145–51.
23. Chuang YC, Chuang HY, Lin TK, et al. Effects of long-term anti-epileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia. 2012;53:120–8.
24. Kim DW, Lee SY, Shon YM, et al. Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy. Epilepsia. 2013;54:146–9.